BriaCell Therapeutics Corp. (BCTX) Earnings History
Annual and quarterly earnings data from 2006 to 2025
Loading earnings history...
BCTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BCTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export BCTX earnings history in CSV or JSON format
Free sign-in required to download data
BriaCell Therapeutics Corp. (BCTX) Earnings Overview
As of May 8, 2026, BriaCell Therapeutics Corp. (BCTX) reported trailing twelve-month net income of -$38M, reflecting -44.5% year-over-year growth. The company earned $-13.69 per diluted share over the past four quarters.
Looking at the long-term picture, BCTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8,581 in fiscal 2006.
BriaCell Therapeutics Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$164M net income, -297.1% margin), IMVT (-$464M net income), ADCT (-$137M net income, -175.3% margin), BCTX has comparable earnings metrics. Compare BCTX vs NKTR →
BCTX Earnings vs Peers
Earnings metrics vs comparable public companies
BCTX Historical Earnings Data (2006–2025)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$36M | -457.4% | -$38M | $-86.25 | - | - |
| 2024 | -$7M | +76.0% | -$46M | $-59.69 | - | - |
| 2023 | -$27M | +20.1% | -$31M | $-261.86 | - | - |
| 2022 | -$34M | -93.6% | -$19M | $-330.38 | - | - |
| 2021 | -$18M | -256.6% | -$9M | $-585.01 | - | - |
| 2020 | -$5M | +15.0% | -$5M | $-1038.56 | - | - |
| 2019 | -$6M | -7.6% | -$6M | $-1505.30 | - | - |
| 2018 | -$5M | -68.1% | -$5M | $-1798.34 | - | - |
| 2017 | -$3M | -44.2% | -$3M | $-1348.63 | - | - |
| 2016 | -$2M | +36.1% | -$2M | $-1360.30 | - | - |
See BCTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCTX — Frequently Asked Questions
Quick answers to the most common questions about buying BCTX stock.
Is BCTX growing earnings?
BCTX EPS fell to $-13.69, with earnings declining -44.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-38M.
What are BCTX's profit margins?
BriaCell Therapeutics Corp. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are BCTX's earnings?
BCTX earnings data spans 2006-2025. The declining earnings trend is -44.5% YoY. Historical data enables comparison across business cycles.